Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azithromycin + doxycycline
- Development stage
- Phase 3
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination of two antibiotics - azithromycin (a macrolide antibiotic) and doxycycline (a tetracycline antibiotic). Both drugs inhibit bacterial protein synthesis but through different mechanisms. This combination has shown enhanced efficacy compared to monotherapy in treating conditions such as non-gonococcal urethritis, severe scrub typhus, and has demonstrated potential in inhibiting cancer stem cell propagation.
- Other names
- Azithromycin plus DoxycyclineAzithromycin and Doxycycline
02
Targets
Bacterial RibosomeBacterial 50S ribosomal subunitmt-LSU (Large mitochondrial ribosomal subunit)mt-SSU (Small mitochondrial ribosomal subunit)
Beyond the preview
Go deeper on azithromycin + doxycycline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azithromycin + doxycycline.